Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Mar 7;12(9):1412-5.
doi: 10.3748/wjg.v12.i9.1412.

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

Michiya Kobayashi  1 , Junichi Sakamoto, Tsutomu Namikawa, Ken Okamoto, Takehiro Okabayashi, Kengo Ichikawa, Keijiro Araki
Affiliations
Case Reports

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

Michiya Kobayashi et al. World J Gastroenterol. .

Abstract

Aim: To examine the paclitaxel concentrations in plasma and ascites after its intravenous administration in patients with ascites due to peritonitis carcinomatosa resulting from advanced gastric cancer.

Methods: Two patients with ascites due to peritonitis carcinomatosa resulting from gastric cancer were included in this study. The paclitaxel concentrations in plasma and ascites were investigated for 72 h in case 1 and 168 h in case 2 after intravenous administration.

Results: The paclitaxel concentration in plasma peaked immediately after administration, followed by rapid decrease below the threshold value of 0.1 micromol (85 ng/mL) within 24 h. In contrast,the paclitaxel concentration in ascites increased gradually for 24 h after administration to a level consistent with the level found in plasma. After 24 h the level of paclitaxel in ascites and plasma became similar, with the optimal level being maintained up to 72 h following administration.

Conclusion: The concentration of paclitaxel in ascites is maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration. Paclitaxel is a promising drug for the treatment of malignant ascites of gastric cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Concentrations of PTX in plasma and ascites in case 1 administrated with 60 mg/m2 PTX intravenously for 1.5 h.
Figure 2
Figure 2
Concentrations of PTX in plasma and ascites in case 2 administrated with 80 mg/m2 PTX intravenously for 1.5 h.
Figure 3
Figure 3
CT scanning of case 1 showing markedly decreased amount of ascites after 2 courses of the combined chemotherapy of 5-fluorouracil and PTX. A1, A2: before chemotherapy; B1, B2: after chemotherapy.
See this image and copyright information in PMC

References

    1. Rowinsky EK, Donehower RC. Paclitaxel (taxol) N Engl J Med. 1995;332:1004–1014. - PubMed
    1. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, Chi CW. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 1996;77:14–18. - PubMed
    1. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999;85:295–301. - PubMed
    1. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999;22:580–586. - PubMed
    1. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E, Oliynyk P. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer. 1999;85:2347–2351. - PubMed

Publication types

MeSH terms

Substances